SGHT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sight Sciences Inc (SGHT) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are positive analyst ratings and potential growth catalysts for 2026, the company's financial performance has been weak, with declining revenue, net income, and EPS. Additionally, insider selling has significantly increased, and there is no strong trading signal or recent positive news to support an immediate buy decision. The stock may be worth monitoring for future developments, but it does not currently present a compelling entry point.
The MACD is positive and expanding, indicating a potential bullish trend. RSI is neutral at 40.831, and moving averages are converging, suggesting no clear trend. Key support and resistance levels are close to the current price, with a pivot at 5.341, resistance at 5.551, and support at 5.131.
Analyst upgrades with increased price targets, Medicare fee schedule establishment for TearCare, and potential growth in 2026 from both business segments.
Significant insider selling (up 4122.05% last month), declining financial performance in Q3 2025, and no recent news or congress trading data to support a bullish sentiment.
In Q3 2025, revenue dropped by -1.25% YoY to $19.91M, net income declined by -26.18% YoY to -$8.17M, and EPS fell by -27.27% YoY to -0.16. However, gross margin increased by 5.98% YoY to 88.9%.
Analysts are generally bullish on SGHT, with multiple upgrades and price target increases. UBS raised its target to $12, Piper Sandler to $9, and Lake Street to $12, citing growth catalysts and improved market access for TearCare.
